<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665260</url>
  </required_header>
  <id_info>
    <org_study_id>12-01-004</org_study_id>
    <nct_id>NCT02665260</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum</brief_title>
  <official_title>Randomized Pilot Study Investigating the Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if cantharidin is a safe and effective treatment
      for molluscum contagiosum in kids
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blind, placebo-controlled trial. Participants were recruited from the
      Pediatric Dermatology clinic at Montefiore Medical Center. One hundred eligible participants
      were randomly assigned to receive cantharidin 0.7% topical, cantharidin 0.7% topical with
      occlusion, placebo, or placebo with occlusion. Treatments were applied at weeks 0 and 3
      (blinded phase). At week 6, all participants were treated with open-label, topical
      cantharidin 0.7% without occlusion every 3 weeks until all lesions resolved (open-label
      phase).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Achieve Complete Clearance at 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assess number of subjects who achieve a lesion count of zero at 6 weeks (end of open-label phase)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Experienced an Adverse Event</measure>
    <time_frame>33 weeks</time_frame>
    <description>Number of subjects who experienced an adverse event as assessed by patient-reported outcomes questionnaire at each visit</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Molluscum Contagiosum</condition>
  <arm_group>
    <arm_group_label>Cantharidin with occlusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cantharidin 0.7% topical with occlusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cantharidin without occlusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cantharidin 0.7% topical without occlusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with occlusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo topical with occlusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo without occlusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo topical without occlusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cantharidin</intervention_name>
    <description>cantharidin 0.7% topical liquid</description>
    <arm_group_label>Cantharidin with occlusion</arm_group_label>
    <arm_group_label>Cantharidin without occlusion</arm_group_label>
    <other_name>2,6-Dimethyl-4,10-dioxatricyclo-decane-3,5-dione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo topical liquid</description>
    <arm_group_label>Placebo with occlusion</arm_group_label>
    <arm_group_label>Placebo without occlusion</arm_group_label>
    <other_name>flexible collodion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gauze occlusion bandage</intervention_name>
    <description>Gauze occlusion bandage with adhesive tape</description>
    <arm_group_label>Cantharidin with occlusion</arm_group_label>
    <arm_group_label>Placebo with occlusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2-17years

          -  Healthy

          -  &lt;50 molluscum contagiosum lesions

        Exclusion Criteria:

          -  Immunosuppressed

          -  Oral corticosteroids

          -  Sexually active/pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <results_first_submitted>December 6, 2016</results_first_submitted>
  <results_first_submitted_qc>March 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2017</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Steven R Cohen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molluscum Contagiosum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cantharidin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 6 subjects met exclusion criteria for having greater than 50 molluscum contagiosum lesions at screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cantharidin With Occlusion</title>
          <description>Patients treated with cantharidin 0.7% topical with occlusion</description>
        </group>
        <group group_id="P2">
          <title>Cantharidin Without Occlusion</title>
          <description>Patients treated with cantharidin 0.7% topical without occlusion</description>
        </group>
        <group group_id="P3">
          <title>Placebo With Occlusion</title>
          <description>Patients treated with placebo and occlusion</description>
        </group>
        <group group_id="P4">
          <title>Placebo Without Occlusion</title>
          <description>Patients treated with placebo without conclusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cantharidin</title>
          <description>Patients treated with 0.7% topical cantharidin without occlusion</description>
        </group>
        <group group_id="B2">
          <title>Cantharidin With Occlusion</title>
          <description>Patients treated with 0.7% topical cantharidin with occlusion</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Patients treated with placebo without occlusion</description>
        </group>
        <group group_id="B4">
          <title>Placebo With Occlusion</title>
          <description>Patients treated with placebo vehicle with occlusion</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jamaican</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieve Complete Clearance at 6 Weeks</title>
        <description>Assess number of subjects who achieve a lesion count of zero at 6 weeks (end of open-label phase)</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cantharidin With Occlusion</title>
            <description>Patients treated with cantharidin 0.7% topical with occlusion</description>
          </group>
          <group group_id="O2">
            <title>Cantharidin Without Occlusion</title>
            <description>Patients treated with cantharidin 0.7% topical without occlusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo With Occlusion</title>
            <description>Patients treated with placebo and occlusion</description>
          </group>
          <group group_id="O4">
            <title>Placebo Without Occlusion</title>
            <description>Patients treated with placebo without conclusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieve Complete Clearance at 6 Weeks</title>
          <description>Assess number of subjects who achieve a lesion count of zero at 6 weeks (end of open-label phase)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of subjects achieving lesion clearance</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of subjects not achieving lesion clearance</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Experienced an Adverse Event</title>
        <description>Number of subjects who experienced an adverse event as assessed by patient-reported outcomes questionnaire at each visit</description>
        <time_frame>33 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cantharidin</title>
            <description>Patients treated with 0.7% topical cantharidin without occlusion</description>
          </group>
          <group group_id="O2">
            <title>Cantharidin With Occlusion</title>
            <description>Patients treated with 0.7% topical cantharidin with occlusion</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients treated with placebo without occlusion</description>
          </group>
          <group group_id="O4">
            <title>Placebo With Occlusion</title>
            <description>Patients treated with placebo vehicle with occlusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experienced an Adverse Event</title>
          <description>Number of subjects who experienced an adverse event as assessed by patient-reported outcomes questionnaire at each visit</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number experiencing adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number not experiencing adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cantharidin</title>
          <description>Subjects treated with topical cantharidin 0.7% without occlusion</description>
        </group>
        <group group_id="E2">
          <title>Cantharidin With Occlusion</title>
          <description>Subjects treated with topical cantharidin 0.7% with occlusion</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Subjects treated with placebo without occlusion</description>
        </group>
        <group group_id="E4">
          <title>Placebo With Occlusion</title>
          <description>Subjects treated with placebo with occlusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Cohen</name_or_title>
      <organization>Montefiore Medical center</organization>
      <phone>718-920-8470</phone>
      <email>dermpharmeinstein@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

